Sodium channel blockers

Details Sodium channel blockers Sodium channel blockers

2007-03-06

2007-03-06

Tucker, Zachary C (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S255050

Reexamination Certificate

active

10828352

ABSTRACT:
The present invention relates to a compound represented by formula (I):in which at least one of R3and R4is a group represented by formula (A):where the structural variables are as defined herein. The compounds are useful for blocking sodium channels.

REFERENCES:
patent: 3313813 (1967-04-01), Cragoe
patent: 3472848 (1969-10-01), Cragoe, Jr. et al.
patent: 3539569 (1970-11-01), Tull et al.
patent: 3544571 (1970-12-01), Cragoe, Jr., et al.
patent: 3573306 (1971-03-01), Shepard et al.
patent: 3625950 (1971-12-01), Cragoe, Jr.
patent: 3668241 (1972-06-01), Cragoe, Jr. et al.
patent: 3794734 (1974-02-01), Cragoe, Jr. et al.
patent: 3864401 (1975-02-01), Schultz et al.
patent: 3894065 (1975-07-01), Cragoe, Jr. et al.
patent: 3914253 (1975-10-01), Cragoe, Jr. et al.
patent: 3928624 (1975-12-01), Cragoe, Jr. et al.
patent: 3929872 (1975-12-01), Cragoe, Jr. et al.
patent: 3931239 (1976-01-01), Cragoe, Jr. et al.
patent: 3953476 (1976-04-01), Cragoe, Jr. et al.
patent: 3956374 (1976-05-01), Shepard et al.
patent: 3958004 (1976-05-01), Cragoe, Jr. et al.
patent: 3966966 (1976-06-01), Cragoe, Jr. et al.
patent: 3974212 (1976-08-01), Cragoe, Jr. et al.
patent: 3976681 (1976-08-01), Cragoe, Jr. et al.
patent: 3976686 (1976-08-01), Cragoe, Jr. et al.
patent: 3979361 (1976-09-01), Schultz et al.
patent: 3984465 (1976-10-01), Cragoe, Jr. et al.
patent: 3984552 (1976-10-01), Cragoe, Jr. et al.
patent: 3987091 (1976-10-01), Cragoe, Jr. et al.
patent: 3989749 (1976-11-01), Cragoe, Jr. et al.
patent: 3991087 (1976-11-01), Cragoe, Jr. et al.
patent: 3991106 (1976-11-01), Cragoe, Jr. et al.
patent: 4003927 (1977-01-01), Woltersdorf, Jr. et al.
patent: 4006180 (1977-02-01), Cragoe, Jr. et al.
patent: 4012524 (1977-03-01), Cragoe, Jr. et al.
patent: 4025625 (1977-05-01), Rooney et al.
patent: 4067980 (1978-01-01), Cragoe, Jr. et al.
patent: 4085117 (1978-04-01), Cragoe, Jr. et al.
patent: 4085211 (1978-04-01), Cragoe, Jr. et al.
patent: 4085219 (1978-04-01), Cragoe, Jr. et al.
patent: 4087526 (1978-05-01), Cragoe, Jr. et al.
patent: 4087542 (1978-05-01), Cragoe, Jr. et al.
patent: 4092414 (1978-05-01), Cragoe, Jr. et al.
patent: 4100294 (1978-07-01), Cragoe, Jr. et al.
patent: 4105769 (1978-08-01), Rooney et al.
patent: 4140776 (1979-02-01), Cragoe, Jr. et al.
patent: 4145551 (1979-03-01), Cragoe, Jr. et al.
patent: 4159279 (1979-06-01), Smith et al.
patent: 4163781 (1979-08-01), Cragoe, Jr. et al.
patent: 4163794 (1979-08-01), Cragoe, Jr. et al.
patent: 4177285 (1979-12-01), Cragoe, Jr. et al.
patent: 4181727 (1980-01-01), Cragoe, Jr. et al.
patent: 4196292 (1980-04-01), Woltersdorf, Jr. et al.
patent: 4237130 (1980-12-01), Cragoe, Jr. et al.
patent: 4237144 (1980-12-01), Cragoe, Jr. et al.
patent: 4246406 (1981-01-01), Cragoe, Jr. et al.
patent: 4277602 (1981-07-01), Woltersdorf et al.
patent: 4291050 (1981-09-01), Woltersdorf, Jr. et al.
patent: 4296122 (1981-10-01), Cragoe, Jr. et al.
patent: 4298743 (1981-11-01), Cragoe, Jr. et al.
patent: 4317822 (1982-03-01), Woltersdorf, Jr. et al.
patent: 4362724 (1982-12-01), Bock et al.
patent: 4401669 (1983-08-01), Cragoe, Jr. et al.
patent: 6475509 (2002-11-01), Boucher, Jr.
patent: 6995160 (2006-02-01), Johnson
patent: WO 00/23023 (2000-04-01), None
patent: WO 01/05773 (2001-01-01), None
Kellerman, D. “P2Y2 Receptor Agonists. A New Class of Medication Targeted at Improved Mucociliary Clearance” Chest, vol. 121(5), supplement, pp. 201S-205S.
Maria E. Giannakou, et al., “Characterization of theDrosophila melanogasteralkali-metal/proton exchanger (NHE) gene family”, The Journal of Experimental Biology, XP-002381331, vol. 204, No. 21, 2001, pp. 3703-3716.
Pascal Barbry, et al., “Biochemical Identification of Two Types of Phenamil Binding Sites Associated with Amiloride-Sensitive Na+Channels”, Biochemistry, XP-002381332, vol. 28, No. 9, 1989, pp. 3744-3749.
Pascal Barbry, et al., “[3H]Phenamil Binding Protein of the Renal Epithelium Na+Channel. Purification, Affinity Labeling, and Functional Reconstitution”, Biochemistry, XP-002381333, vol. 29, No. 4, 1990, pp. 1039-1045.
Jeanne Velly, et al., “Effects of amiloride and its analogues on [3H]batrachotoxinin-A 20-α benzoate binding, [3H]tetracaine binding and22Na influx”, European Journal of Pharmacology, XP-002381334, vol. 149, No. 1-2, 1988, pp. 97-105.
Thomas R. Kleyman, et al., “The Cellular Pool of Na+Channels in the Amphibian Cell Line A6 Is Not Altered by Mineralocorticoids”, The Journal of Biological Chemistry, XP-002381335, vol. 264, No. 20, Jul. 15, 1989, pp. 11995-12000.
R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches,Molecular Cell, vol. 8, 149-158, Jul. 2001.
Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, p. 301-316, 1992.
Louis Simchowitz et al.,An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, p. 9-25, 1992.
J.R. Sabater et al., Aerosolization of P2y2-Receptor Agonists Enhances Mucociliary Clearance in Sheep,The American Physiological Society, p. 2191-2196, 1999.
Thomas R. Kleyman et al., Amiloride and Its Analogs as Tools in the Study of Ion Transport,The Journal of Membrane Biology, vol. 105, pp. 1-21, 1988.
Edward C. Taylor et al., A Facile Route to “Open Chain” Analogues of DDATHF,Heterocycles, vol. 28, No. 2, 1989.
Paul-Michael Windscheif et al., Substituted Dipyridlethenes and -ethynes and Key Pyridine Building Blocks,Synthesis, pp. 87-92, Jan. 1994.
Edward J. Cragoe, Jr.,The Synthesis of Amiloride and Its Analogs, p. 24-38, Chapter 3, 1992.
Jack H. Li, et al., Stereoselective Blockage of Amphibian Epithelial Sodium Channels by Amiloride Analogs,The Journal of Pharmacology and Experimental Therapeutics, vol. 267, No. 3, pp. 1081-1084, 1993.
Pallav L. Shah, M.D.,Chapter 7, Progress in the Treatment of Pulmonary Disease in Cystic Fibrosis, Annual Reports in Medicinal Chemistry, vol. 36, pp. 67-76, 2001.
Dieter Worlitzsch et al., Effects of Reduced Mucus Oxygen Concentration in Airway Pseudomonas Infections of Cystic Fibrosis Patients,The Journal of Clinical Investigation, Feb. 2002, vol. 109, No. 3, pp. 317-336.
Edward J. Cragoe, Jr., et al., Chapter 7: Diuretic Agents,Annual Reports in Medicinal Chemistry, 1966, p. 59-68.
Edward J. Cragoe, Jr., et al., Chapter 7: Diuretic Agents,Annual Reports in Medicinal Chemistry, 1965, p. 67-77.
Robert L. Smith, et al., Chapter 8: Diuretics,Annual Reports in Medicinal Chemistry, vol. 11, pp. 71-79, 1976.
Robert L. Smith, et al., Chapter 7: Diuretics,Annual Reports in Medicinal Chemistry, vol. 13, pp. 61-70, 1978.
Edward J. Cragoe, Jr., Structure-Activity Relationships in the Amiloride Series,Merck Sharp and Dohme Research Laboratories, 1979, pp. 1-20.
J. B. Bicking, et al., J. Med. Chem., vol. 8, No. 5, pp. 638-642, “Pyrazine Diuretics. I. N-Amidino-3-6-Halopyrazinecarboxamides”, 1965.
R. F. Epand, et al., British Journal of Cancer, vol. 63, No. 2, pp. 247-251, “Reversal of Intrinsic Multidrug Resistance in Chinese Hamster Ovary Cells by Amiloride Analogs”, 1991.
T. M. Cocks, et al., British Journal of Pharmacology, vol. 95, No. 1, pp. 67-76, 1988.
T. R. Kleyman, et al., American Journal of Physiology, vol. 260, No. 2, Pt. 1, pp. C271-C276, 1991.
K. E. Barrett, et al., Annual Rev. Physiol. vol. 2000, No. 62, pp. 535-572.
R.F. Epand, et al., “Reversal of Intrinsic Multidrug Resistance in Chinese Hamster Ovary Cells by Amiloride Analogs”, Br. J. Cancer (1991), 63, pp. 247-251.
Kim E. Barrett, et al., “Chloride Secretion by the Intestinal Epithelium: Molecular Basis and Regulatory Aspects”, Annu. Rev. Physiol. 2000, 62, pp. 535-572.
Form PCT/IPEA/408, Written Opinion for International Application No. PCT/US03/04817, filed Feb. 19, 2003.

Affiliated with

Also associated with

Rating

Sodium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sodium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sodium channel blockers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3742059